Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (12): 1131-1137.doi: 10.35541/cjd.20220919
• Original Articles • Previous Articles Next Articles
Zhang Ying1, Zhang Chunlei1, Wang Wenhui1, Zhang Hua2, Wang Xiaoyu1, Zhou Xin1, Guo Jinzhu1
Received:
2022-12-27
Revised:
2023-08-26
Online:
2023-12-15
Published:
2023-12-05
Contact:
Guo Jinzhu
E-mail:guojinzhu_826@163.com
Supported by:
Zhang Ying, Zhang Chunlei, Wang Wenhui, Zhang Hua, Wang Xiaoyu, Zhou Xin, Guo Jinzhu. Comparative analysis of metabolic indicators in patients with persistent and non-persistent psoriasis[J]. Chinese Journal of Dermatology, 2023, 56(12): 1131-1137.doi:10.35541/cjd.20220919
[1] | Chen L, Shen Z. Tissue⁃resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders[J]. Cell Mol Immunol, 2020,17(1):64⁃75. doi: 10.1038/ s41423⁃019⁃0291⁃4. |
[2] | Masson Regnault M, Shourick J, Jendoubi F, et al. Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review[J]. Am J Clin Dermatol, 2022,23(4):433⁃447. doi: 10.1007/s40257⁃022⁃00679⁃y. |
[3] | Owczarek W, Dzik M, Narbutt J, et al. Real⁃world evidence on time to relapse of plaque psoriasis after discontinuation of biologic treatment in Poland[J]. Dermatol Ther, 2021,34(5):e15052. doi: 10.1111/dth.15052. |
[4] | Smith CH, Jabbar⁃Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017[J]. Br J Dermatol, 2017,177(3):628⁃636. doi: 10.1111/bjd.15665. |
[5] | Smith CH, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update[J]. Br J Dermatol, 2020,183(4):628⁃637. doi: 10.1111/bjd.19039. |
[6] | Souza CS, de Castro C, Carneiro F, et al. Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: quality of life and prevalence[J]. J Dermatol, 2019,46(1):3⁃10. doi: 10.1111/1346⁃8138.14706. |
[7] | Pan Y, Tian T, Park CO, et al. Survival of tissue⁃resident memory T cells requires exogenous lipid uptake and metabolism[J]. Nature, 2017,543(7644):252⁃256. doi: 10.1038/nature21379. |
[8] | Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid⁃binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome[J]. Clin Chem, 2006,52(3):405⁃413. doi: 10.1373/clinchem.2005.062463. |
[9] | Yeung DC, Wang Y, Xu A, et al. Epidermal fatty⁃acid⁃binding protein: a new circulating biomarker associated with cardio⁃metabolic risk factors and carotid atherosclerosis[J]. Eur Heart J, 2008,29(17):2156⁃2163. doi: 10.1093/eurheartj/ehn295. |
[10] | Ibarretxe D, Girona J, Amigó N, et al. Impact of epidermal fatty acid binding protein on 2D⁃NMR⁃assessed atherogenic dyslipidemia and related disorders[J]. J Clin Lipidol, 2016,10(2):330⁃338.e2. doi: 10.1016/j.jacl.2015.12.012. |
[11] | Kralisch S, Fasshauer M. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?[J]. Diabetologia, 2013,56(1):10⁃21. doi: 10. 1007/s00125⁃012⁃2737⁃4. |
[12] | Tso AW, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10⁃year prospective study in a Chinese cohort[J]. Diabetes Care, 2007,30(10):2667⁃2672. doi: 10.2337/ dc07⁃0413. |
[13] | Xu A, Tso A W, Cheung B M, et al. Circulating adipocyte⁃fatty acid binding protein levels predict the development of the metabolic syndrome: a 5⁃year prospective study[J]. Circulation, 2007,115(12):1537⁃1543. doi: 10.1161/circulationaha.106.647503. |
[14] | Alotaibi HA. Effects of weight loss on psoriasis: a review of clinical trials[J]. Cureus, 2018,10(10):e3491. doi: 10.7759/cureus.3491. |
[15] | 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华心血管病杂志, 2016,44(10):833⁃853. doi: 10.3760/cma.j.issn.0253⁃3758.2016. 10.005. |
[16] | Duan MM, Ma YX, Zhang JZ, et al. Analysis of clinical features of patients with psoriasis and metabolic syndrome in Xinjiang[J/OL]. Int J Dermatol Venereol, 2023. doi: 10.1097/JD9.0000000 000000287. [published online ahead of print 2023⁃01⁃10]. |
[17] | Blauvelt A, Armstrong AW, Langley RG, et al. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate⁃to⁃severe plaque psoriasis: results from the ECLIPSE study[J]. J Dermatolog Treat, 2022,33(4):2317⁃2324. doi: 10.1080/09546634.2021.1959504. |
[18] | Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry[J]. J Am Acad Dermatol, 2022,86(1):68⁃76. doi: 10.1016/j.jaad.2021.06.883. |
[19] | Al⁃Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial[J]. Expert Opin Biol Ther, 2014,14(6):749⁃756. doi: 10.1517/14712598. 2014.900541. |
[20] | Warren RB, Carrascosa JM, Fumero E, et al. Time to relapse after tildrakizumab withdrawal in patients with moderate⁃to⁃severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial[J]. J Eur Acad Dermatol Venereol, 2021,35(4):919⁃927. doi: 10.1111/jdv.16964. |
[21] | Stinco G, Balato N, Buligan C, et al. A multicenter retrospective case⁃control study on Suspension of TNF⁃inhibitors and Outcomes in Psoriatic patients (STOP study)[J]. G Ital Dermatol Venereol, 2019,154(4):392⁃399. doi: 10.23736/S0392⁃0488.18.06156⁃4. |
[22] | Baran A, Świderska M, Bacharewicz⁃Szczerbicka J, et al. Serum fatty acid⁃binding protein 4 is increased in patients with psoriasis[J]. Lipids, 2017,52(1):51⁃60. doi: 10.1007/s11745⁃016⁃4211⁃4. |
[23] | Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs⁃⁃mechanisms and therapeutic implications[J]. Nat Rev Endocrinol, 2015,11(10):592⁃605. doi: 10.1038/nrendo.2015.122. |
[24] | Kozłowska D, Myśliwiec H, Harasim⁃Symbor E, et al. Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis[J]. Mol Biol Rep, 2021,48(5):4421⁃4429. doi: 10.1007/s11033⁃021⁃06461⁃3. |
[25] | Owczarczyk⁃Saczonek A, Czerwiñska J, Orylska M, et al. Effect of methotrexate treatment on the expression of epidermal⁃fatty acid⁃binding protein (E⁃FABP) and apolipoproteins in patients with psoriasis[J]. Postepy Dermatol Alergol, 2020,37(3):401⁃406. doi: 10.5114/ada.2020.96109. |
[26] | Yilmaz E, Tamer E, Artüz F, et al. Evaluation of serum uric acid levels in psoriasis vulgaris[J]. Turk J Med Sci, 2017,47(2):531⁃534. doi: 10.3906/sag⁃1512⁃5. |
[27] | Gui XY, Jin HZ, Wang ZJ, et al. Serum uric acid levels and hyperuricemia in patients with psoriasis: a hospital⁃based cross⁃sectional study[J]. An Bras Dermatol, 2018,93(5):761⁃763. doi: 10.1590/abd1806⁃4841.20187547. |
[28] | Elmets CA, Leonardi CL, Davis D, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities[J]. J Am Acad Dermatol, 2019,80(4):1073⁃1113. doi: 10.1016/j.jaad.2018.11. 058. |
[29] | Yanai H, Adachi H, Hakoshima M, et al. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease[J]. Int J Mol Sci, 2021, 22(17): 9221. doi: 10.3390/ijms22179221. |
[30] | Chi CC, Wang J, Chen YF, et al. Risk of incident chronic kidney disease and end⁃stage renal disease in patients with psoriasis: a nationwide population⁃based cohort study[J]. J Dermatol Sci, 2015,78(3):232⁃238. doi: 10.1016/j.jdermsci.2015.03.012. |
[31] | Chiu HY, Hui RC, Tsai TF, et al. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an 8⁃year multicenter study[J]. J Am Acad Dermatol, 2023,88(1):71⁃78. doi: 10.1016/j.jaad.2019.01. 035. |
[32] | Beygi S, Lajevardi V, Abedini R. C⁃reactive protein in psoriasis: a review of the literature[J]. J Eur Acad Dermatol Venereol, 2014,28(6):700⁃711. doi: 10.1111/jdv.12257. |
[33] | Hagino T, Saeki H, Kanda N. Biomarkers and predictive factors for treatment response to tumor necrosis factor⁃α inhibitors in patients with psoriasis[J]. J Clin Med, 2023,12(3):974. doi:10.3390/jcm12030974. |
[1] | Chen Xingyu, Yao Xu. Role of neutrophils in inflammatory dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220865-e20220865. |
[2] | Wu Yubing, Wang Xiaoyu, An Binyi, Wu Yingying, Sang Hong, Kong Qingtao, . Role of cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes signaling pathway in the occurrence of psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230394-e20230394. |
[3] | Zhu Tingting, Zhang Xuejun. Apremilast in the treatment of plaque psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230448-e20230448. |
[4] | Hao Dan, Wang Yiyi, Xiao Yue, Yan Wei, Li Wei. Systemic treatment options for psoriasis in special areas [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230190-e20230190. |
[5] | Wang Shiqi, Wang Aiping, Li Hang, Li Ruoyu. Comparison of dermoscopic features of toenail psoriasis and fingernail psoriasis [J]. Chinese Journal of Dermatology, 2024, 57(2): 161-165. |
[6] | Fu Dandan, Li Jialin, Fu Xiuyu, Zhang Xinyu, Hu Hua, Song Xiangfeng, Tian Zhongwei. S100A10 protein expression in psoriatic lesions and its effect on psoriasis-like skin inflammation in mouse models [J]. Chinese Journal of Dermatology, 2023, 56(9): 839-844. |
[7] | Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 56(9): 845-848. |
[8] | Shen Chunping, Li Ping, Luo Xiaoyan, Liang Yuan, Liu Ying, Zhao Mutong, Wang Shan, Tian Jing, Jiao Lei, Wang Yang, Luo Zhen, Yu Shijuan, Fang Xiao, Wang Hua, Ma Lin . Efficacy of daily use of a test emollient combined with topical glucocorticoids applied at the weekend for delaying the recurrence of atopic dermatitis in children during the maintenance period: a randomized, blank-controlled, multicenter clinical study [J]. Chinese Journal of Dermatology, 2023, 56(8): 756-762. |
[9] | Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802. |
[10] | Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692. |
[11] | Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650. |
[12] | Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition) [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625. |
[13] | Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705. |
[14] | Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517. |
[15] | China Dermatologist Association, Chinese Society of Dermatology, Xijing Hospital, Air Force Medical University, Chinese Dietary Guideline for Psoriasis Patients Task Force. Dietary guideline for patients with psoriasis in China (2023) [J]. Chinese Journal of Dermatology, 2023, 56(5): 389-401. |
|